Skip to main content

Clinical Trials Using Pembrolizumab

Review the clinical trials studying pembrolizumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 276-300 of 430

Pembrolizumab and Hypofractionated Radiation Therapy after Surgery for the Treatment of Mucosal Melanoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
APL-2 and Pembrolizumab versus APL-2, Pembrolizumab and Bevacizumab versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Ruxolitinib in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphomas
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Neoadjuvant Enfortumab Vedotin and Pembrolizumab for the Treatment of Patients with Upper Tract Urothelial Cancer, NEPTUNE Trial
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Immunotherapy (Pembrolizumab) with Chemotherapy and Chemoradiation for the Treatment of Stage II-IVb Squamous Cell Cancer of the Nasal Cavity and Paranasal Sinuses, the I-NAPA Study
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Intratumoral Vusolimogene Oderparepvec in Combination with Pembrolizumab for the Treatment of Locally Advanced Unresectable or Metastatic Angiosarcoma
Status: Active
Location: University of California San Francisco, San Francisco, California
Pembrolizumab in Combination with Gemcitabine and Cisplatin for Treating Patients with High-Risk Resectable Intrahepatic Cholangiocarcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Reduced Adjuvant Systemic Therapy for the Treatment of Patients with Early Breast Cancer Who Experienced a Pathological Complete Response After Neoadjuvant Systemic Therapy and Do Not Have Molecular Residual Disease, MolecularPCR Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pulsed Dose Chemotherapy Plus Pembrolizumab for First Line Treatment of Recurrent or Metastatic HNSCC
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Pembrolizumab with 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: University of California San Francisco, San Francisco, California
Lenvatinib and Pembrolizumab for the Treatment of Locally Advanced or Unresectable Well Differentiated G3 Neuroendocrine Tumors
Status: Active
Location: University of California San Francisco, San Francisco, California
Enfortumab Vedotin and Pembrolizumab Induction with Pembrolizumab Maintenance for the Treatment of Locally Advanced Unresectable or Metastatic Urothelial Carcinoma
Status: Active
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Lenvatinib and Pembrolizumab for the Treatment of Unresectable, Locally Advanced, or Metastatic Anorectal Squamous Cell Cancer
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Pembrolizumab and Lenvatinib for the Treatment of Patients with Metastatic and Recurrent Cervical Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Azacitidine and Pembrolizumab for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
First Line Chemotherapy (Carboplatin and Paclitaxel) and Immunotherapy (Pembrolizumab) for the Treatment of Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active
Location: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Reduced Dose Chemotherapy in Combination with Immunotherapy for the Treatment of Stage IV Non-small Cell Lung Cancer in Vulnerable or Older Adults with a PD-L1 Tumor Proportion Score < 50%
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
De-escalated Pembrolizumab Monotherapy after Pembrolizumab Plus Enfortumab Vedotin for the Treatment of Unresectable, Locally Advanced, or Metastatic Urothelial Cancer in Patients with Circulating Tumor Deoxyribonucleic Acid Response, CT-READ Trial
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Gemcitabine, Cisplatin, and Pembrolizumab before and after Surgery for the Treatment of Potentially Resectable Biliary Tract Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York